Creative BioMolecules Appoints Five New Members to Management Team

Hopkinton, MA, July 9, 1997--Creative BioMolecules, Inc. (Nasdaq: CBMI) today announced that it has appointed five (5) new members to its management team. The Company named Sean Evans, R.Ph., Ph.D., as Senior Director of Formulations and Analytical Sciences, Philip Fantasia as Senior Director of Regulatory Affairs and Quality, Daniel Ellis, Ph.D., as Director of Program Management, Ron Marchesani as Director of Quality Control, and David Shea as Director of Information Services.

"These appointments continue Creative BioMolecules’ commitment to building a top level management team with the experience in research, development and regulatory affairs to accelerate our product development programs," said Michael Tarnow, President and Chief Executive Officer. "The forthcoming commercialization of our lead product in bone fracture repair therapy with our partner Stryker Corporation, the ongoing preclinical trials of our renal therapy in conjunction with Biogen, Inc. and the expansion of our proprietary product development programs will be enhanced by the talents and commitment of the expanded management team."

Sean Evans, R.Ph., Ph.D., joins Creative from ImmuLogic Pharmaceutical Corporation where he held the position of Director for the Formulation Development, Analytical Sciences, and Clinical Supplies departments. Prior to ImmuLogic, Dr. Evans was an Associate Scientist at Bristol-Myers Squibb Company and held a variety of formulation scientist positions at Interferon Sciences, Inc., both in New Jersey. Dr. Evans holds a B.S. in Pharmacy and a Ph.D. in Pharmaceutical Sciences, both from Rutgers University.

Philip Fantasia joins Creative from Behring Diagnostics, Inc. where he held the position of Director, Scientific Affairs. Previous to Behring, Mr. Fantasia was Director, Regulatory Affairs for Molecular Biosystems, Inc. where he successfully led the company to the FDA approval of its flagship product, the first ultrasound imaging agent on the U.S. market. Mr. Fantasia brings to Creative a history of managing ISO 9001 registration, as well as successful negotiations and product approvals with the FDA and other Federal and state agencies.

Daniel B. Ellis, Ph.D., joins Creative with 20 years experience at Hoechst-Roussel Pharmaceuticals, Inc. where he held management positions as Department Head for Preclinical Development and Project Management, Associate Director of Biological Research and Manager of Biochemistry and Drug Metabolism. Dr. Ellis holds a Ph.D. in Biochemistry from McGill University in Montréal, Canada.

Ron Marchesani joins Creative from Immulogic Pharmaceutical Corporation where he held the position of Director of Quality Assurance and Quality Control. Prior to Immulogic, Mr. Marchesani served as manager of Quality Control at Genzyme Corporation and held various Quality positions at Henkel Corporation, Armour Pharmaceuticals Company and Medi-Physics, Inc., in Illinois and Florida.

David Shea joins Creative from MediSense, Incorporated where he was Director of Information Services. MediSense is a Massachusetts based manufacturer of blood glucose sensors. Prior to joining MediSense, Mr. Shea was a Consulting Manager at Andersen Consulting in Boston, a systems integration and software consulting company.

The statements in this news release are not historical facts and include forward-looking statements that involve risks and uncertainties. Factors which could cause actual results to differ from the Company’s expectations include, without limitation, the course of the research and development programs, including the achievement of development milestones by the Company, the impact of competitive products, the timely receipt of regulatory clearances required for clinical testing, manufacturing and marketing of products and the other risks and uncertainties detailed from time to time in the Company’s periodic reports.

Creative BioMolecules, Inc. is a discovery and development company focused on proprietary therapeutics for human tissue regeneration and restoration. The Company’s therapeutics are based on proteins that act as signals in initiating and regulating the cellular events involved in tissue and organ formation.

NOTE: Creative BioMolecules, Inc. makes available its latest news releases on the Internet at or by facsimile by calling Fax On Demand at 1-800-758-5804, extension 212213.


For additional information on this news release, please contact the Company.

map | resources
Copyright © 1998 Creative BioMolecules, Inc. All Rights Reserved
Last modified: November 10, 1998
Important Legal Information